Zoom buttonMenu button

Home> News

News

WND ranks 18th among nation's biomedical parks

(wndonline.cn)Updated: 2024-11-13

1731478207669060255.png

The 2024 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report is released on Oct 31. [Photo/WeChat account: xinwu_wx]

The 2024 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report was recently released, revealing WND's record-breaking 18th spot on the list.

In 2023, WND's biomedical industry continued to lead the charge in Wuxi, with its industrial scale exceeding 100 billion yuan ($14.09 billion) for the first time, representing 52.3 percent of the city's total.

By the end of 2023, WND had accumulated 56 Class III medical devices and 477 Class II medical devices that have been approved for registration, with a total of 155 clinical trials conducted. Sunvozertinib, an innovative drug from Dizal Pharma, has received the first approval of a locally originated drug in Wuxi over a decade, while four products from biomedical companies such as Nutricia and Hengyi Health Technology have received certificates for food for special medical purposes.

In an effort to enhance the comprehensive competitiveness of its biomedical industry, WND is set to optimize support in terms of policies, capital, platforms, and lands.

Media Center

News
Videos
  • 366 206.jpg
  • 366-206.jpg
Leave Your Message Here
About
Overview
Why WND
Contact Us
Media Center
News
Videos
Investment Guides
Investment Procedures
Utilities and Safety
Preferential Policies
Talent Pool
Regulatory Bodies
Advisory Institutions
Q & A
Business
Key Industries
Industrial Parks
Star Companies
Culture & Tourism
Events
Attractions
Specialties
Living
Transportation
Education
Healthcare
Visa
Shopping
Accommodation
Useful Info
日本語|한국어
All rights reserved. Presented by China Daily.